Health Canada has approved the updated Pfizer-BioNTech vaccine that protects against one of the most recently circulating COVID-19 virus variants.
This mRNA vaccine, called “Comirnaty,” now targets the Omicron KP.2 subvariant, while the previous version of the Pfizer-BioNTech vaccine targeted the Omicron XBB.1.5 subvariant.
Health Canada recently asked provinces and territories to discard their old COVID-19 vaccines to ensure the most recent vaccine is used during this fall’s respiratory virus season.
Comirnaty is the third updated COVID-19 vaccine approved by Health Canada for this season, following last week’s authorization of Moderna’s mRNA vaccine Spikevax and Novavax’s protein-based vaccine Nuvaxovid.
Both Pfizer and Moderna’s vaccines are approved for adults and children six months and older. Novavax’s is approved for adults and children 12 years and older.
—
The Canadian Press’ health content is funded through a partnership with the Canadian Medical Association. Editorial choices are solely the responsibility of The Canadian Press.
To see in video